Načítá se...
Reassessing the Role of Surrogate Endpoints in Drug Development for Heart Failure
With few notable exceptions, drug development for heart failure (HF) has become progressively more challenging and there remain no definitively proven therapies for patients with acute HF or HF with preserved ejection fraction. Inspection of temporal trends suggests an increasing rate of disagreemen...
Uloženo v:
| Vydáno v: | Circulation |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6205720/ https://ncbi.nlm.nih.gov/pubmed/30354535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.034668 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|